<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="80020">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02063672</url>
  </required_header>
  <id_info>
    <org_study_id>CL0018-01</org_study_id>
    <nct_id>NCT02063672</nct_id>
  </id_info>
  <brief_title>Lutonix® Drug Coated Balloon vs. Standard Balloon Angioplasty for Treatment of Femoropopliteal In-Stent Restenosis</brief_title>
  <acronym>SFA ISR</acronym>
  <official_title>A Prospective, Multicenter, Single-Blind, Randomized, Controlled Trial Comparing the Lutonix® Drug Coated Balloon vs. Standard Balloon Angioplasty for Treatment of Femoropopliteal In-Stent Restenosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>C. R. Bard</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>C. R. Bard</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the safety and efficacy of the Lutonix Drug Coated Balloon for treatment of
      femoropopliteal artery (SFA) in-stent restenosis (ISR).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Actual">February 13, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy: Primary Patency</measure>
    <time_frame>12 Months</time_frame>
    <description>Primary patency is defined as freedom from clinically driven TLR and from Binary Restenosis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: Freedom from all cause perioperative death, index limb amputation, index limb reintervention and index limb related death.</measure>
    <time_frame>30 Days and 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Primary and Secondary Patency (DUS PSVR &lt;2.5)</measure>
    <time_frame>6, 12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Revascularization (TLR)</measure>
    <time_frame>6, 12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Rutherford classification from baseline</measure>
    <time_frame>6, 12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of resting Ankle Brachial Index (ABI) from baseline</measure>
    <time_frame>6, 12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Walking Impairment Questionnaire from baseline</measure>
    <time_frame>6, 12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life from baseline, as measured by EQ-5D</measure>
    <time_frame>6, 12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major vascular complications (≤30 day)</measure>
    <time_frame>6, 12 and 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Femoral Artery Stenosis</condition>
  <condition>Femoral Artery Occlusion</condition>
  <condition>Restenosis</condition>
  <arm_group>
    <arm_group_label>Lutonix DCB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lutonix Paclitaxel Drug Coated Balloon</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PTA Catheter</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard Uncoated Balloon Angioplasty Catheter</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lutonix DCB</intervention_name>
    <arm_group_label>Lutonix DCB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard Uncoated Balloon Angioplasty Catheter</intervention_name>
    <description>PTA Catheter</description>
    <arm_group_label>PTA Catheter</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Male or non-pregnant female ≥18 years of age

          2. Rutherford Clinical Category 2-4

          3. Significant (≥ 50%) restenosis of a previous bare (not covered and not drug-eluting)
             nitinol stent(s) in the femoropopliteal artery

          4. Lesion measures between 4 and 18 cm

          5. Target vessel diameter between ≥4 and ≤6 mm and able to be treated with available
             device size matrix

          6. A patent inflow artery free from significant lesion (≥50% stenosis) as confirmed by
             angiography

          7. Successful crossing and predilatation of the target lesion with a guidewire

          8. At least one patent native outflow artery to the ankle, free from significant (≥50%)
             stenosis as confirmed by angiography that has not previously been (nor planned to be)
             revascularized

          9. No other prior vascular or surgical interventions within 2 weeks before and/or
             planned 30 days after the protocol treatment

        Key Exclusion Criteria:

          1. Life expectancy of &lt;1 year

          2. Patient is currently participating in an investigational drug or other device study
             or previously enrolled in this study NOTE: Enrollment in another drug or device
             clinical trial during the follow up period is not allowed

          3. History of stroke within 3 months

          4. History of MI, thrombolysis or angina within 2 weeks of enrollment

          5. Prior vascular surgery of the index limb, with the exception of remote common femoral
             patch angioplasty separated by at least 2 cm from the target lesion

          6. Target lesion involves a previously placed covered stent or drug-eluting stent

          7. Grade 4 or 5 stent fracture (mal-aligned components or trans-axial spiral
             configuration) in the restenotic stent

          8. Inability to take required study medications or allergy to contrast that cannot be
             adequately managed with pre- and post-procedure medication

          9. Known inadequate distal outflow (&gt;50 % stenosis of distal popliteal and/or all three
             tibial vessels), or planned future treatment of vascular disease distal to the target
             lesion

         10. Intended use of adjunctive treatment modalities (i.e. laser, atherectomy, cryoplasty,
             scoring/cutting balloon, stents, etc.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos Mena, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiology Associates</name>
      <address>
        <city>Fairhope</city>
        <state>Alabama</state>
        <zip>36532</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedStar Health Research Institute</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiology and Imaging Specialists of Lakeland, P.A.</name>
      <address>
        <city>Lakeland</city>
        <state>Florida</state>
        <zip>33805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital Research Institute</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metropolitan Hospital d/b/a Metro Health Hospital</name>
      <address>
        <city>Wyoming</city>
        <state>Michigan</state>
        <zip>49519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis Radiology and Vascular Research Foundation</name>
      <address>
        <city>Plymouth</city>
        <state>Minnesota</state>
        <zip>55441</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hattiesburg Clinic, PA</name>
      <address>
        <city>Hattiesburg</city>
        <state>Mississippi</state>
        <zip>39401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jackson Heart Clinic, P.A.</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City Vascular Foundation</name>
      <address>
        <city>North Kansas City</city>
        <state>Missouri</state>
        <zip>64116</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hunterdon Cardiovascular Associates</name>
      <address>
        <city>Flemington</city>
        <state>New Jersey</state>
        <zip>08822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rex Hospital, Inc.</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TriHealth, Inc.</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Miriam Hospital - A Lifespan Partner</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wellmont Cardiology Services, Inc.</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Branch</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aurora Medical Group</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 30, 2017</lastchanged_date>
  <firstreceived_date>February 12, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
